Hola

Home

 / 

Treatment Considerations

Treatment Considerations

Treating advanced soft tissue sarcomas

Leiomyosarcoma

Classified as uterine or nonuterine

Liposarcoma

Subtypes2:

  • Myxoid/Round Cell
  • Well-differentiated
  • Pleomorphic
  • Dedifferentiated
*

Percentages based on incidence data from 1978-2001 collected in the 9 Surveillance, Epidemiology and End Results (SEER) program areas. Cases of soft tissue sarcoma were categorized into major histologic types and subtypes, according to criteria specified in the 2002 World Health Organization Classification of Tumors and the recommendations of an expert pathologist. Additional cases that met the morphologic criteria of soft tissue sarcoma regardless of primary site, except bones and joints, were added for a total of 26,758 cases used in the analysis.

Treating patients with unresectable or metastatic leiomyosarcoma or liposarcoma

Treatment considerations should include tumor characteristics3:

Chemosensitivity of histological subtype3

Natural history3

Tumor burden3

Tumor stage4

Tumor grade4

Clinical characteristics:

Patient’s general condition and level of symptoms3

Comorbidities3

Previous treatments3

Patient goals3

Delaying disease progression is one measure of treatment success in advanced soft tissue sarcoma5

Progression-free survival (PFS) is the time from randomization to objective tumor progression or death.5

PFS allows new treatments to be evaluated in smaller studies and over shorter periods of time, and results are not confounded by subsequent lines of therapy.5

Explore a treatment option for liposarcoma and leiomyosarcoma.

CONSIDER YONDELIS® (trabectedin)

YONDELIS® is the only treatment, after an anthracycline-containing regimen, approved specifically for both:

  • Unresectable or metastatic liposarcoma6-8
  • Unresectable or metastactic leiomyosarcoma6-8

Read about the efficacy of YONDELIS®

REFERENCES:

  1. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CDM, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922-2930.
  2. Henze J, Bauer S. Liposarcomas. Hematol Oncol Clin N Am. 2013;27(5):939-955.
  3. Blay J-Y, Sleijfer S, Schöffski P, et al. International expert opinion on patient-tailored management of soft tissue sarcomas. Eur J Cancer. 2014;50(4):679-689.
  4. Ramu EM, Houdek MT, Isaac CE, Dickie CI, Ferguson PC, Wunder JS. Management of soft-tissue sarcomas; treatment strategies, staging, and outcomes. SICOT J. 2017;3:20. doi:10.1051/sicotj/2017010
  5. Chmielowski B, Federman N, Tap WD. Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas. Expert Rev Anticancer Ther. 2012;12(9):1217-1228.
  6. YONDELIS® (trabectedin) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  7. HALAVEN® (eribulin) [Prescribing Information]. Nutley, NJ: Eisai Inc.
  8. VOTRIENT® (pazopanib) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.

Index

  • Treating advanced soft tissue sarcomas
  • Treating patients with unresectable or metastatic leiomyosarcoma or liposarcoma
  • Delaying disease progression is one measure of treatment success in advanced soft tissue sarcoma

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND IMPORTANT SAFETY INFORMATION

EXPAND Expand isi